Healthcare

Technology Developments in Synthetic Biology for Drug Discovery and Diagnostics

Advances in DNA, RNA, Protein Printing, and Automation Technologies to Drive Adoption of Synthetic Biology in the Next Three Years

INDUSTRY
Healthcare

RELEASE DATE
29-Nov-2021
REGION
DELIVERABLE TYPE
Technology Research

RESEARCH CODE
DA28-01-00-00-00
SKU
HC03479-GL-TR_26018
Yes
SHARE

Technology Developments in Synthetic Biology for Drug Discovery and Diagnostics
Published on: 29-Nov-2021 | SKU: HC03479-GL-TR_26018

Need more details?

$4,950.00

$3,712.50 save 25 %

DownloadLink
Need more details?

The conventional drug discovery and diagnostics technologies are unable to cope up with the current disease management practices. To this end, researchers have explored possibilities beyond life sciences. Specifically, they have figured out that the use of engineering principles to biological systems can revolutionize the drug discovery and diagnostics field. This is when synthetic biology has started gathering interest. Synthetic biology involves technologies like DNA/RNA/protein/tissue printing, gene regulatory circuits, Clustered Regularly Interspersed Short Palindromic Repeats (CRISPR)?Cas, xenonucleic acids (XNA), and branched DNA. Most of these technologies are enabled by well-established technologies of machine learning, artificial intelligence, automation, and microfluidics.
DNA printing technology is at the heart of synthetic biology based drug discovery as it can design a library of thousands of DNA molecule in a very short time. This technology can help build various genetic circuits to synthetic viral genomes. Genetic circuits can act as either the drug molecules or biosensors. The DNA printers can be modified to print RNA/XNA/protein molecules. This technology is enabled by microfluidics, which can be modified to print tissues and organs, thereby producing various disease models for toxicity testing. CRISPR?Cas technology can serially characterize multiple genes, thereby helping in drug target identification. Alternatively, CRIPR?Cas based genetic circuits can serve as good diagnostic tools to detect viruses, bacteria, as well as cancers. XNA or smart nucleotide bases and branched DNA technologies leverage diagnostics to the level above next generation sequencing both in terms of time and cost. The enablers serve as icing on a cake. Biofoundries expedite the Design, Build, Test, and Learn (DBTL) cycle; automation brings in the continuity and accuracy in the experimentation; and machine learning helps reduce the number of iteration of experiments. Altogether, these technologies accomplish the best outcomes in drug discovery and diagnostics.
This report describes each of these technologies in detail and portrays the true potential of them. It also discusses the applications of synthetic biology as well as the drivers and challenges in the adoption of synthetic biology in drug discovery and diagnostics. Further, the report enlightens about the funding opportunities, the types of funding in this area, key companies, and investors. Overall, we believe that synthetic biology has evolved drug discovery for high success rate and diagnostics for early detection with the overall diminished healthcare burden.
Key questions:
•     What are the driving factors for research and adoption of synthetic biology in drug discovery and diagnostics?
•     What challenges and impediments remain to the adoption of synthetic biology?
•     What initiatives are industry participants undertaking to accelerate adoption?
•     What are the specialized synthetic biology platforms expected business outcomes compared to conventional diagnostics and drug discovery?


Have questions about this research or need deeper insights?
Speak directly with our analytics experts for tailored recommendations.

Recent related Healthcare research

19 Nov 2026   |   Global   |   Technology Research

Programmable Vaccines: AI-Designed Antigens and Next-Generation Rapid Platforms

Traditional vaccine development is an empirical, time-consuming process that often leads to a high failure rate. With the proven clinical success of RNA vaccines, there has been a focus on accelerating the development of vaccines to address the growing incidence of infectious diseases and emerging p...

17 Nov 2026   |   Global   |   Frost Radar

Frost Radar™: Quantum-Grade Sensor Technology Ecosystem for Healthcare Applications, 2026

Quantum-grade sensors are advancing healthcare by leveraging quantum phenomena to enable highly sensitive, precise, and non-invasive measurements of biological signals and physiological parameters. These innovations enhance diagnostic accuracy, disease monitoring, brain activity measurement, and ear...

16 Nov 2026   |   North America   |   Frost Radar

Frost Radar™: Healthcare Data Interoperability Platforms and Integration Engines in North America, 2026

This Frost Radar™ analyzes the healthcare data platform and integration engine vendors that enable healthcare organization to improve the exchange, utilization, contextualization, and management of clinical, operational, financial, and administrative data. Data issues, AI adoption, and solution gove...

03 Nov 2026   |   North America   |   Market Research

Enterprise Imaging Market, United States, 2025–2030

Enterprise imaging is no longer a technology upgrade. It is becoming the operating model for imaging across the provider organization, and the next investment cycle will decide which vendors lead it. This study gives vendors, ecosystem partners, and provider leaders a 360-degree view of that shift, ...

02 Nov 2026   |   Global   |   Market Research

Continuous Glucose Monitoring Market, Global, 2026

The global continuous glucose monitoring (CGM) market is undergoing a fundamental transformation as the technology evolves from a prescription-led glucose monitoring device into an AI-connected metabolic intelligence ecosystem. Market expansion is increasingly driven by the emergence of over-the-cou...

 

Purchase includes:
  • Report download
  • Growth Dialog™ with our experts

Growth Dialog™

A tailored session with you where we identify the:
  • Strategic Imperatives
  • Growth Opportunities
  • Best Practices
  • Companies to Action

Impacting your company's future growth potential.